Cargando…
In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate
The biopharmaceutical industry has become increasingly focused on developing biosimilars as less expensive therapeutic products. As a consequence, the regulatory approval of 2 antibody-drug conjugates (ADCs), Kadcyla® and Adcetris® has led to the development of biosimilar versions by companies locat...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058630/ https://www.ncbi.nlm.nih.gov/pubmed/27380163 http://dx.doi.org/10.1080/19420862.2016.1204502 |